CompletedPhase 1

Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin

An Open-Label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Lecozotan SR and a Single Oral Dose of Digoxin When Administered Orally to Healthy Adult Subjects

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Asset

Lecozotan

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criterion

•Age 18-55

Primary endpoint

•Evaluation of the effects of multiple doses of lecozotan SR on the PK profile

Identifiers

Registered as

Org study ID3098B1-1142

NCT IDNCT00563732

Timeline

Milestones

Study first posted2007-11-26estimated

Study start2007-12 (month precision)

Primary completion2008-09actual (month precision)

Study completion2008-09actual (month precision)

Last update posted2008-09-09estimated

Assets

Drug assets

Lecozotan

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Women of non childbearing potential and men aged 18 to 55 years at screening.

•Body mass index (BMI) in the range of 18 to 30 kg/m2 and body weight 50 kg (BMI = weight (kg)/[height (m)]

Exclusion criteria

•Presence or history of any disorder that may prevent the successful completion of the study.

•Any clinically important deviation from normal limits in physical examination, vital signs or clinical laboratory test results.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Evaluation of the effects of multiple doses of lecozotan SR on the PK profile of a single dose of digoxin in healthy adult subjects

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.